US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
DE3303707A1
(de)
|
1983-02-04 |
1984-08-09 |
Dynamit Nobel Ag, 5210 Troisdorf |
Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
JPH01167840A
(ja)
|
1987-12-24 |
1989-07-03 |
Konica Corp |
新規な写真用シアンカプラー
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
WO1992018106A1
(en)
|
1991-04-16 |
1992-10-29 |
Nippon Shinyaku Co., Ltd. |
Method of manufacturing solid dispersion
|
HU227530B1
(en)
|
1991-11-22 |
2011-07-28 |
Warner Chilcott Company |
Delayed-release compositions containing risedronate and process for their production
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
EP0665010B1
(en)
|
1992-10-16 |
2002-09-11 |
Nippon Shinyaku Company, Limited |
Method of manufacturing wax matrices
|
GB9226855D0
(en)
|
1992-12-23 |
1993-02-17 |
Erba Carlo Spa |
Vinylene-azaindole derivatives and process for their preparation
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US6326469B1
(en)
|
1994-04-22 |
2001-12-04 |
Sugen, Inc. |
Megakaryocytic protein tyrosine kinases
|
CA2220451A1
(en)
|
1995-05-17 |
1996-11-21 |
Cedars-Sinai Medical Center |
Methods and compositions for improving digestion and absorption in the small intestine
|
US5593997A
(en)
|
1995-05-23 |
1997-01-14 |
Pfizer Inc. |
4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
|
US5994348A
(en)
|
1995-06-07 |
1999-11-30 |
Sanofi |
Pharmaceutical compositions containing irbesartan
|
CH690773A5
(de)
|
1996-02-01 |
2001-01-15 |
Novartis Ag |
Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
|
WO1997049706A1
(en)
|
1996-06-25 |
1997-12-31 |
Novartis Ag |
SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
|
HUP0001507A3
(en)
|
1997-03-19 |
2002-01-28 |
Abbott Gmbh & Co Kg |
Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
|
DK0901786T3
(da)
|
1997-08-11 |
2007-10-08 |
Pfizer Prod Inc |
Faste farmaceutiske dispersioner med foröget biotilgængelighed
|
DE69808670T2
(de)
|
1997-12-31 |
2003-07-03 |
Choongwae Pharma Corp., Seoul/Soul |
Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
MXPA00010150A
(es)
|
1998-04-17 |
2002-05-14 |
Parker Hughes Inst |
Inhibidores de btk y metodos para su identificacion y uso.
|
US7122207B2
(en)
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
US20050287596A9
(en)
|
1998-06-26 |
2005-12-29 |
Braisted Andrew C |
Novel ligands and libraries of ligands
|
US6998233B2
(en)
|
1998-06-26 |
2006-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
UA74141C2
(uk)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
ES2307482T3
(es)
|
1999-02-10 |
2008-12-01 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas.
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
SK3812002A3
(en)
|
1999-09-17 |
2003-09-11 |
Abbott Gmbh & Co Kg |
Pyrazolopyrimidines as therapeutic agents
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
MXPA02003364A
(es)
|
1999-10-06 |
2002-08-23 |
Boehringer Ingelheim Pharma |
Compuestos heterociclicos utiles como inhibidores de las cinasas de tirosina.
|
AU4508601A
(en)
|
1999-11-30 |
2001-06-18 |
Parker Hughes Institute |
Inhibitors of collagen-induced platelet aggregation
|
CA2394650A1
(en)
|
1999-12-17 |
2001-06-21 |
Chi B. Vu |
Novel heterocycles
|
GB0005345D0
(en)
|
2000-03-06 |
2000-04-26 |
Mathilda & Terence Kennedy Ins |
Methods of treating sepsis septic shock and inflammation
|
GB0108903D0
(en)
|
2000-10-05 |
2001-05-30 |
Aventis Pharm Prod Inc |
Novel crystalline forms of a factor Xa inhibitor
|
CA2426508A1
(en)
|
2000-10-23 |
2002-05-16 |
Bristol-Myers Squibb Company |
Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
|
AU2002232492A1
(en)
|
2000-12-06 |
2002-06-18 |
Pharmacia Corporation |
Rapidly dispersing pharmaceutical composition comprising effervescent agents
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
US8306897B2
(en)
|
2001-05-04 |
2012-11-06 |
Stockshield, Inc. |
Method and system for insuring against investment loss
|
US20030114467A1
(en)
|
2001-06-21 |
2003-06-19 |
Shakespeare William C. |
Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
|
US20030124028A1
(en)
|
2001-08-10 |
2003-07-03 |
Carlson Eric D. |
Apparatuses and methods for creating and testing pre-formulations and systems for same
|
US20040248906A1
(en)
|
2001-08-10 |
2004-12-09 |
Donato Nicholas J |
Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
|
WO2003016338A1
(en)
|
2001-08-15 |
2003-02-27 |
Parker Hughes Institute |
Crystal structure of the btk kinase domain
|
IL161409A0
(en)
|
2001-11-21 |
2004-09-27 |
Sunesis Pharmaceuticals Inc |
Methods for ligand discovery
|
US20050084905A1
(en)
|
2002-03-21 |
2005-04-21 |
Prescott John C. |
Identification of kinase inhibitors
|
GB2388594A
(en)
|
2002-05-16 |
2003-11-19 |
Bayer Ag |
Imidazo-triazine PDE 4 inhibitors
|
AU2003257094A1
(en)
|
2002-08-08 |
2004-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted benzimidazole compounds
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
US7687506B2
(en)
|
2003-04-11 |
2010-03-30 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
US20050008640A1
(en)
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
EP1473039A1
(en)
|
2003-05-02 |
2004-11-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
WO2005005429A1
(en)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
|
US8131475B2
(en)
|
2003-09-03 |
2012-03-06 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
CA2537254A1
(en)
|
2003-09-03 |
2005-03-17 |
Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
CN1897950A
(zh)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
稠合芳基和杂芳基衍生物及其使用方法
|
ATE525377T1
(de)
|
2003-10-15 |
2011-10-15 |
Osi Pharm Inc |
Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
|
AU2003297904A1
(en)
|
2003-12-12 |
2005-07-14 |
University Of Maryland, Baltimore |
Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
|
US20050153990A1
(en)
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
BRPI0418031A
(pt)
|
2003-12-22 |
2007-04-17 |
Gilead Sciences Inc |
inibidores de quinase fosfonato-substituìdos
|
RU2006122517A
(ru)
|
2004-01-08 |
2008-02-20 |
Вайет (Us) |
Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779
|
WO2005095406A1
(en)
|
2004-01-26 |
2005-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
US20060025383A1
(en)
|
2004-02-03 |
2006-02-02 |
Neil Wishart |
Aminobenzoxazoles as therapeutic agents
|
ITMI20041314A1
(it)
|
2004-06-30 |
2004-09-30 |
Nuvera Fuel Cells Europ Srl |
Dispositivo di raffreddamento per celle a combustibili a membrana
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
US20060079494A1
(en)
|
2004-09-27 |
2006-04-13 |
Santi Daniel V |
Specific kinase inhibitors
|
CA2582225A1
(en)
|
2004-09-28 |
2006-04-06 |
Mingde Xia |
Substituted dipiperdine ccr2 antagonists
|
BRPI0517619A
(pt)
|
2004-11-10 |
2008-10-14 |
Cgi Pharmaceuticals Inc |
entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos
|
GB0425035D0
(en)
|
2004-11-12 |
2004-12-15 |
Novartis Ag |
Organic compounds
|
UA93673C2
(ru)
|
2005-03-07 |
2011-03-10 |
Баер Шеринг Фарма Акциенгезельшафт |
Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
|
MX2007011041A
(es)
|
2005-03-10 |
2008-02-22 |
Cgi Pharmaceuticals Inc |
Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
|
EP1891066B1
(en)
|
2005-05-13 |
2010-12-22 |
Irm, Llc |
Compounds and compositions as protein kinase inhibitors
|
US20110178097A1
(en)
|
2005-05-23 |
2011-07-21 |
Novartis Ag |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
|
WO2007002433A1
(en)
|
2005-06-22 |
2007-01-04 |
Plexxikon, Inc. |
Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
|
US20070065449A1
(en)
|
2005-09-16 |
2007-03-22 |
Claire Verschraegen |
Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
|
CA2629314A1
(en)
|
2005-11-12 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Tec kinase inhibitors
|
BRPI0621027A2
(pt)
|
2006-01-13 |
2011-11-29 |
Pharmacyclics Inc |
composto, composição farmacêutica
|
ES2420834T3
(es)
|
2006-01-30 |
2013-08-27 |
The Scripps Research Institute |
Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero
|
EP2001498A4
(en)
|
2006-03-20 |
2013-01-23 |
Vertex Pharma |
PHARMACEUTICAL COMPOSITIONS
|
PT2004654E
(pt)
|
2006-04-04 |
2013-08-27 |
Univ California |
Derivados de pirazolopirimidina para utilização como antagonistas da quinase
|
US8604031B2
(en)
|
2006-05-18 |
2013-12-10 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
DE102006026583A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
|
EP2532235A1
(en)
|
2006-09-22 |
2012-12-12 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
ES2403546T3
(es)
|
2006-11-03 |
2013-05-20 |
Pharmacyclics, Inc. |
Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
|
FI20080352A0
(fi)
|
2008-05-09 |
2008-05-09 |
Atacama Labs Oy |
Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
|
CN101674813A
(zh)
|
2007-01-22 |
2010-03-17 |
诺瓦瓦克斯股份有限公司 |
水溶性差的药物的用于减小进食/禁食差异性和改善口服生物利用度的多相药物制剂
|
NL2000640C2
(nl)
|
2007-03-05 |
2008-09-08 |
Stichting Wetsus Ct Of Excelle |
Werkwijze en systeem voor het zuiveren van een vloeistof.
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
MX2009010284A
(es)
|
2007-03-28 |
2010-01-29 |
Pharmacyclics Inc |
Inhibidores de la tirosina-cinasa de bruton.
|
US20090010911A1
(en)
|
2007-04-06 |
2009-01-08 |
Iowa State University Research Foundation, Inc. |
Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
|
PL2142529T3
(pl)
|
2007-04-27 |
2014-06-30 |
Purdue Pharma Lp |
Antagoniści trpv1 i ich zastosowania
|
BRPI0815659A2
(pt)
|
2007-07-30 |
2014-09-30 |
Ardea Biosciences Inc |
Derivados de n-(arilamino) sulfonamidas incluindo polimorfos como inibidores de mek bem como composições, métodos de uso e métodos para preparar os mesmos
|
US7982036B2
(en)
|
2007-10-19 |
2011-07-19 |
Avila Therapeutics, Inc. |
4,6-disubstitued pyrimidines useful as kinase inhibitors
|
EP2426109B1
(en)
|
2007-10-23 |
2013-12-18 |
F. Hoffmann-La Roche AG |
Novel kinase inhibitors
|
US8426441B2
(en)
|
2007-12-14 |
2013-04-23 |
Roche Palo Alto Llc |
Inhibitors of bruton's tyrosine kinase
|
US20150152115A1
(en)
|
2007-12-27 |
2015-06-04 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
CA2905541C
(en)
|
2008-01-09 |
2020-02-11 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
AU2009235426A1
(en)
|
2008-04-09 |
2009-10-15 |
Lek Pharmaceuticals D.D. |
Granulation of active pharmaceutical ingredients
|
JP2011518786A
(ja)
|
2008-04-14 |
2011-06-30 |
アルデア バイオサイエンシズ,インコーポレイティド |
調製及び使用のための組成物及び方法
|
EP2123626A1
(en)
|
2008-05-21 |
2009-11-25 |
Laboratorios del Dr. Esteve S.A. |
Co-crystals of duloxetine and co-crystal formers for the treatment of pain
|
US8450335B2
(en)
|
2008-06-27 |
2013-05-28 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
EP3311818A3
(en)
|
2008-07-16 |
2018-07-18 |
Pharmacyclics, LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
CN102245027A
(zh)
|
2008-07-29 |
2011-11-16 |
尖端科学公司 |
四(n-烷基吡啶)-卟啉衍生物用于杀死微生物或防止微生物生长的用途
|
TR201106844T2
(tr)
*
|
2008-10-09 |
2012-02-21 |
Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ |
Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi.
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
US8765754B2
(en)
|
2009-04-29 |
2014-07-01 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
AU2010295690B2
(en)
|
2009-09-16 |
2016-07-28 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
MY189483A
(en)
|
2010-05-31 |
2022-02-16 |
Ono Pharmaceutical Co |
Purinone derivative
|
MX2020004501A
(es)
|
2010-06-03 |
2021-11-09 |
Pharmacyclics Llc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
US20120071497A1
(en)
*
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
HUE032515T2
(en)
|
2010-06-23 |
2017-09-28 |
Hanmi Science Co Ltd |
New condensed pyrimidine derivatives for inhibiting tyrosine kinase activity
|
CN103096716B
(zh)
|
2010-08-10 |
2016-03-02 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐
|
CN105541849B
(zh)
|
2010-08-12 |
2018-03-23 |
勃林格殷格翰国际有限公司 |
6‑环烷基‑1,5‑二氢‑吡唑并[3,4‑d]嘧啶‑4‑酮衍生物及其作为PDE9A抑制剂的用途
|
US8541391B2
(en)
|
2010-10-28 |
2013-09-24 |
Viropharma Incorporated |
Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
|
US8501484B2
(en)
|
2011-03-14 |
2013-08-06 |
Los Alamos National Security, Llc |
Preparation of cerium halide solvate complexes
|
MX2011004759A
(es)
|
2011-05-04 |
2012-11-21 |
Senosiain S A De C V Lab |
Nuevas formas solidas de antibioticos.
|
PT2710005T
(pt)
|
2011-05-17 |
2016-11-16 |
Principia Biopharma Inc |
Inibidores de tirosina-quinase
|
WO2013012959A1
(en)
*
|
2011-07-18 |
2013-01-24 |
Tokai Pharmaceuticals, Inc. |
Novel compositions and methods for treating prostate cancer
|
DK2751109T3
(da)
|
2011-09-02 |
2017-01-23 |
Incyte Holdings Corp |
Heterocyclylaminer som pi3k-inhibitorer
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
EP4218740A1
(en)
|
2012-01-13 |
2023-08-02 |
XSpray Pharma AB (publ) |
Novel compositions
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
JP5514256B2
(ja)
|
2012-05-18 |
2014-06-04 |
株式会社東芝 |
磁気記憶素子及びその製造方法
|
TWI662963B
(zh)
|
2012-06-04 |
2019-06-21 |
美商製藥有限責任公司 |
布魯頓氏酪胺酸激酶抑制劑之結晶形式
|
DK2861599T3
(da)
|
2012-06-18 |
2020-03-02 |
Principia Biopharma Inc |
Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
|
US20150140085A1
(en)
*
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
KR20180088926A
(ko)
|
2012-07-24 |
2018-08-07 |
파마싸이클릭스 엘엘씨 |
브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
|
CN103121999A
(zh)
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
一种酪氨酸激酶抑制剂pci-32765的合成方法
|
JP2015537033A
(ja)
|
2012-11-15 |
2015-12-24 |
ファーマサイクリックス,インク. |
キナーゼ阻害剤としてのピロロピリミジン化合物
|
EP2983670A4
(en)
|
2013-04-08 |
2017-03-08 |
Pharmacyclics LLC |
Ibrutinib combination therapy
|
RU2019134551A
(ru)
|
2013-05-30 |
2019-11-22 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
US20160067241A1
(en)
|
2013-06-13 |
2016-03-10 |
Dennis M. Brown |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
|
JP6800750B2
(ja)
|
2013-08-02 |
2020-12-16 |
ファーマサイクリックス エルエルシー |
固形腫瘍の処置方法
|
US10253244B2
(en)
|
2013-09-04 |
2019-04-09 |
Halliburton Energy Services, Inc. |
Scale-inhibiting cocrystals for treatment of a subterranean formation
|
EP3044338B1
(en)
|
2013-09-12 |
2021-11-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
CN104447701B
(zh)
|
2013-09-17 |
2019-03-22 |
广东东阳光药业有限公司 |
吡唑类衍生物及其用途
|
EA201690746A1
(ru)
|
2013-10-25 |
2016-12-30 |
Фармасайкликс Элэлси |
Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
|
WO2015071432A1
(en)
*
|
2013-11-14 |
2015-05-21 |
Sandoz Ag |
Pharmaceutical compositions of ibrutinib
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
WO2015095772A2
(en)
|
2013-12-20 |
2015-06-25 |
Emory University |
Formulations and methods for targeted ocular delivery of therapeutic agents
|
CN105949198A
(zh)
|
2014-01-29 |
2016-09-21 |
苏州晶云药物科技有限公司 |
依鲁替尼的新晶型及其制备方法
|
EP3102190A4
(en)
|
2014-02-07 |
2017-09-06 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
WO2015123654A1
(en)
|
2014-02-17 |
2015-08-20 |
The Cleveland Clinic Foundation |
Amine passivated nanoparticles for cancer treatment and imaging
|
US20150238490A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
US20150267752A1
(en)
|
2014-03-19 |
2015-09-24 |
Roller Bearing Company Of America, Inc. |
Bearing outer race having a radially inwardly biased seal
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
WO2015145415A2
(en)
|
2014-03-27 |
2015-10-01 |
Perrigo Api Ltd. |
Ibrutinib solid forms and production process therefor
|
CN105085529A
(zh)
|
2014-05-15 |
2015-11-25 |
广东东阳光药业有限公司 |
依鲁替尼新晶型及其制备方法
|
US9127069B1
(en)
*
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
WO2016007617A2
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting, Llc. |
Pharmaceutical compounding kit
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
WO2016020697A1
(en)
|
2014-08-06 |
2016-02-11 |
Cipla Limited |
Pharmaceutical compositions of polymeric nanoparticles
|
MX2017001671A
(es)
|
2014-08-07 |
2017-07-04 |
Pharmacyclics Llc |
Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
|
CA2958139A1
(en)
|
2014-08-14 |
2016-02-18 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
US10059715B2
(en)
|
2014-10-01 |
2018-08-28 |
Ratiopharm Gmbh |
Acid addition salt of ibrutinib
|
CN104523695A
(zh)
*
|
2014-11-12 |
2015-04-22 |
广东东阳光药业有限公司 |
一种治疗过度增生性疾病的药物组合物
|
CN105640961A
(zh)
|
2014-11-18 |
2016-06-08 |
山东瑞禾医药科技有限公司 |
一种含依鲁替尼的药物组合物
|
WO2016079216A1
(en)
|
2014-11-20 |
2016-05-26 |
Sandoz Ag |
Physical forms of ibrutinib, a bruton's kinase inhibitor
|
US20150224060A1
(en)
|
2015-01-03 |
2015-08-13 |
David Wong |
Gastric retentive tablet compositions
|
CZ201584A3
(cs)
|
2015-02-09 |
2016-08-17 |
Zentiva, K.S. |
Sůl Ibrutinib sulfátu
|
RU2017133663A
(ru)
|
2015-03-03 |
2019-04-03 |
Др. Редди'С Лабораторис Лимитед |
П0лиморфы ибрутиниба
|
ES2971597T3
(es)
*
|
2015-03-03 |
2024-06-06 |
Pharmacyclics Llc |
Formulaciones farmacéuticas del inhibidor de la tirosina quinasa de Bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
KR102618114B1
(ko)
|
2015-04-02 |
2023-12-27 |
라티오팜 게엠베하 |
이브루티닙과 카복실산의 공결정체
|
WO2016164404A1
(en)
|
2015-04-06 |
2016-10-13 |
Janssen Pharmaceutica Nv |
Compositions containing ibrutinib
|
CN105294696A
(zh)
|
2015-11-19 |
2016-02-03 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
CN105440040B
(zh)
|
2015-12-23 |
2018-03-13 |
浙江京新药业股份有限公司 |
依鲁替尼的纯化方法
|
JP7336195B2
(ja)
*
|
2016-01-19 |
2023-08-31 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Btk阻害剤を含む製剤/組成物
|
EP3405177A1
(en)
*
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica NV |
Formulations/compositions comprising a btk inhibitor
|
CN105646499A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型g及制备方法
|
CN105646484A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
晶型b及制备方法
|
CN105646498A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型f及制备方法
|
CN106619643A
(zh)
|
2016-11-11 |
2017-05-10 |
上海雅本化学有限公司 |
一种含依鲁替尼的药物组合物
|